Tripos Introduces Advanced Protein Modeling Software With SYBYL 7.3
ST. LOUIS–(BUSINESS WIRE)–Tripos, Inc. (Nasdaq: TRPS), a leading provider of drug discovery informatics products and chemistry research, today announced the release of Advanced Protein Modeling, an innovative new discovery software product that combines the best methods for homolog identification, sequence alignment and fast interactive comparative protein structure modeling.
Advanced Protein Modeling is now available as an optional component of Tripos’ market-leading SYBYL® 7.3 product line, and is based on the FUGUE™ and ORCHESTRAR™ technologies, developed by Professor Sir Tom Blundell, Ph.D., and his research team at the University of Cambridge, England. Professor Blundell is a fellow of the Royal Society, a member of the European Molecular Biology Organization and the first recipient of the Pfizer European Prize for Innovation, among many other awards. He is also a founding member of the Academy of Medical Sciences and the co-founder of Astex Technologies Ltd.
“What sets Advanced Protein Modeling apart is its extensive knowledgebase of protein family and structural information, and its ability to focus on each specific aspect of the model-building process,” Blundell said. “We set out to solve some of the problems in protein structure prediction by leveraging the knowledge generated about protein structures during the past 20 years. This novel approach has yielded excellent predictions of three-dimensional protein structures which are not yet experimentally accessible.”
Comparative protein modeling predicts a protein’s unique three-dimensional structure, representing the shape into which the protein naturally folds, and also indicates the protein’s biological function. These predicted three-dimensional structures are essential for structure-based drug design when experimental data are unavailable.
“With the release of Advanced Protein Modeling, we have significantly enhanced the receptor-based drug design portion of our SYBYL modeling portfolio,” said Dr. Robert Clark, vice president of scientific research and director of the Tripos Informatics Research Center. “The release of this product demonstrates our ongoing commitment to support the CADD community with novel science and technology, not only through our own internal research programs, but also through our network of scientific collaborators at leading research institutions, such as Professor Blundell and his group at the University of Cambridge.”
Those wanting more information about Advanced Protein Modeling should visit http://www.Tripos.com/APMod or contact their local Tripos representative.
About Tripos, Inc.
Tripos (Nasdaq: TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Within Tripos’ Discovery Informatics business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos’ Discovery Research business, Tripos’ medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com.
Tripos and the Tripos logo are registered trademarks of Tripos, Inc., and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners.
